Kamada is a drug manufacturers - specialty & generic business based in the US. Kamada shares (KMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.62 – an increase of 1.85% over the previous week. Kamada employs 420 staff and has a trailing 12-month revenue of around $161 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.62 |
|---|---|
| 52-week range | $4.61 - $8.90 |
| 50-day moving average | $6.94 |
| 200-day moving average | $6.12 |
| Wall St. target price | $14.40 |
| PE ratio | 26 |
| Dividend yield | $0 (3%) |
| Earnings per share (TTM) | $0.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.58 from 2025-04-23
| 1 week (2025-04-17) | 1.23% |
|---|---|
| 1 month (2025-03-25) | -7.06% |
| 3 months (2025-01-24) | -8.48% |
| 6 months (2024-10-25) | 24.62% |
| 1 year (2024-04-25) | 26.54% |
|---|---|
| 2 years (2023-04-25) | 51.08% |
| 3 years (2022-04-25) | 24.88% |
| 5 years (2020-04-24) | 7.1939 |
Valuing Kamada stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kamada's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kamada's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Kamada shares trade at around 26x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Kamada's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9382. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Kamada's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Kamada's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $32.4 million.
The EBITDA is a measure of a Kamada's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $161 million |
|---|---|
| Operating margin TTM | 13.02% |
| Gross profit TTM | $70 million |
| Return on assets TTM | 3.45% |
| Return on equity TTM | 5.75% |
| Profit margin | 8.98% |
| Book value | $4.51 |
| Market Capitalization | $383.6 million |
TTM: trailing 12 months
Dividend payout ratio: 76.92% of net profits
Recently Kamada has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Kamada shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Kamada's case, that would currently equate to about $0 per share.
Kamada's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Kamada's most recent dividend payout was on 6 April 2025. The latest dividend was paid out to all shareholders who bought their shares by 16 March 2025 (the "ex-dividend date").
Over the last 12 months, Kamada's shares have ranged in value from as little as $4.608 up to $8.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kamada's is 0.282. This would suggest that Kamada's shares are less volatile than average (for this exchange).
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.